Search results
Find out all the key statistics for CureVac N.V. (CVAC), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Jun 8, 2022 · * Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's ...
May 23, 2024 · Net financial result for the first quarter of 2024 amounted to €3.4 million, or an increase of €0.4 million, from €3.0 million for the same period in 2023. This increase was mainly driven by ...
Nov 15, 2023 · Greetings, and welcome to the CureVac Financial Results for Third Quarter and First 9 Months of 2023 business update. (Operator Instructions) As a reminder, this conference is being recorded.
May 28, 2024 · This new Phase 2 study in the joint CureVac/GSK seasonal influenza program has been initiated following interim data from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal ...
Find the latest CureVac N.V. (NL0015436031.SG) stock quote, history, news and other vital information to help you with your stock trading and investing.
Nov 11, 2022 · / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced data from the ...
